Recruiting

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

ClinicalTrials.gov IDNCT07075718

PhasePHASE2

Enrollment110

SponsorGlaukos Corporation

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Glaucoma

About this study

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Interventions

Drug: Gen 2 Travoprost Intracameral Implant — travoprost
Drug: Timolol eye drops 0.5% — timolol 0.5%
Procedure: Sham Procedure — sham implant administration
Other: Placebo eye drops — artificial tears

Primary outcomes

Intraocular pressure (IOP) (3 months)

Eligibility information

Inclusion Criteria: * Diagnosis of open-angle glaucoma or ocular hypertension in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye

Study locations

Glaukos Investigative Site, Grand Junction, Colorado 81501 United States
Glaukos Investigative Site, Oklahoma City, Oklahoma 73112 United States
Glaukos Clinical Site, El Paso, Texas 79922 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.